Double Bond Pharmaceutical International AB

Double Bond Pharmaceutical, DBP, is a pharmaceutical company. The main focus is on the treatment of severe forms of cancer, infections and autoimmune diseases. The research is based on the company's proprietary technology. The products are sold under separate trademarks and collaboration on product development is done together with other players in the field. The company is based in Uppsala.

Quotes for Double Bond Pharmaceutical International AB

Created with Highstock 6.0.7CloseTraded Volume3. mar10. mar17. mar24. mar31. mar7. apr21. apr28. apr5. maj12. maj19. maj26. maj0.250.30.350.40.450200T400T600T800T

Right Now

+/-
0.02
%
7,69%
Latest
0.28
High
0.28
Low
0.28
Volume
2 590
Turnover (SEK)
725
Market Value (MSEK)
29,7
Time (Latest trade)
2025-05-28 12:20

Board

CEO

  • Igor Lokot

Chairperson of the Board

  • Sanna Rejnlander

Board

  • Igor Lokot
  • Irina Zaitseva
  • Sergey Yanitsky
  • Articles of association

    • News

    Show More

    News agencies

    Show More

    Analysis

    Videos

    BeloGal® and SA-033 (english)

    Aktiespararna intervjuar VD Igor Lokot

    Double Bond sitdown

    BeloGal® and SA-033 (svenska)

    BeloGal® and SA-033 (english)

    Aktiespararna intervjuar VD Igor Lokot

    Double Bond sitdown

    BeloGal® and SA-033 (svenska)

    Largest Owners

    Name Capital % Votes % Date
    Igor Lokot 9,01 16,06 2025-03-27
    KSDR Hamberg AB 7,82 7,21 2025-03-27
    Per Ahlström 7,74 7,14 2025-03-27
    Carl Carvalho 4,02 3,71 2025-03-27
    QQM Fund Management AB 3,73 3,44 2025-04-30
    Investentia AB 3,19 2,95 2025-03-27
    Lars-Åke Börje Flarke 3,19 2,94 2025-03-27
    Avanza Pension 2,79 2,58 2025-03-27
    Magnus Hamberg 2,57 2,37 2025-03-27
    Thomas Trumstedt 2,15 1,98 2025-03-27
    ** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

    Insider trading

    NameTransaction DateTypeInstrumentAmountPriceValueCurrency
    Sanna Rejnlander2022-07-13en-USOption i samband med incitamentsprogram 1 000 0000,0113 000,0SEK
    Irina Zaitseva2022-07-13en-USOption i samband med incitamentsprogram 1 000 0000,0113 000,0SEK
    Igor Lokot2022-07-13en-USOption i samband med incitamentsprogram 3 000 0000,0139 000,0SEK
    Igor Lokot2021-05-12Sell TransactionDBP Ser B- 27 969 0000,01−323 405,5SEK
    Yulia Mamaeva2021-05-21en-USDouble Bond Pharmaceutical BTU B 22 7491,4332 531,1SEK
    Igor Lokot2021-01-20Sell TransactionDouble Bond Pharmaceutical B- 377 0002,25−848 250,0SEK
    Igor Lokot2020-02-22Sell TransactionDouble Bond Pharmaceutical International AB ser B TR- 9 700 0000−0,0SEK
    Igor Lokot2020-02-22Sell TransactionDouble Bond Pharmaceutical International AB ser B Teckningsrätt- 9 700 0000−0,0SEK
    Yulia Mamaeva2020-02-28en-USDouble Bond Pharmaceutical B 30 3331,7553 082,8SEK
    Igor Lokot2020-02-28en-USDouble Bond Pharmaceutical B 80 8081,75141 414,0SEK
    Yulia Mamaeva2019-04-09Sell TransactionDouble Bond Pharmaceutical UR - 91 0000−91,0SEK
    Igor Lokot2019-04-09Sell TransactionDouble Bond Pharmaceutical UR- 242 4240−242,4SEK
    Igor Lokot2019-04-05Sell TransactionDouble Bond Pharmaceutical UR- 9 700 0000,01−48 500,0SEK
    Igor Lokot2019-02-13Sell TransactionDouble Bond Pharmaceutical B- 100 0008−800 000,0SEK
    Igor Lokot2018-11-16Sell TransactionDouble Bond Pharmaceutical B- 400 00011,33−4 532 000,0SEK
    Igor Lokot2018-04-19en-USDBP BTA B 242 4241,65399 999,6SEK
    Igor Lokot2018-04-06en-USDBP BTA B 2 550 0001,654 207 500,0SEK
    Yulia Mamaeva2018-04-06en-USDBP B BTA 22 7501,6537 537,5SEK
    Igor Lokot2016-10-21en-USDouble Bond Pharmaceutical B- 500 0007,4−3 700 000,0SEK
    *Source: Holdings by Modular Finance AB. Compiled and processed data from the Swedish Financial Supervisory Authority

    Key Numbers

    2025-03-312024-12-312024-12-312024-09-302024-06-302024-03-312023-12-31
    Number of months that the report spans Q1 3 Months2024Q4 3 MonthsQ3 3 MonthsQ2 3 MonthsQ1 3 Months2023
    Total revenue MSEK0.001.090.220.230.200.441.37
    Earnings before interest and tax MSEK-0.40-7.76-1.92-1.72-2.06-2.06-13.44
    Profit before tax MSEK-1.10-13.24-4.95-0.93-4.87-2.49-17.34
    Net profit MSEK-1.10-13.24-4.95-0.93-4.87-2.49-17.34
    Earnings per share SEK-0.00-0.00-0.00-0.00-0.00-0.00-0.00
    Dividend per share SEK0.000.00
    Equity MSEK2.90-2.13-2.132.833.766.515.36
    Fixed assets MSEK0.070.090.090.100.120.140.17
    Intangible assets MSEK7.940.100.100.130.150.180.20
    Current assets MSEK3.765.605.602.603.782.785.02
    Total asset MSEK11.766.226.226.727.128.9711.60
    Long term liabilities MSEK0.000.000.000.590.000.000.00
    Current liabilities MSEK8.868.358.353.893.372.466.24
    Number of shares SEK107.12107.12107.12107.12107.12102.0395.35
    *Compiled data from Millistream

    Upcoming reports

    • 2025-06-23 Årsstämma 2024

    • 2025-08-26 Delårsrapport 2025-Q2

    • 2025-11-25 Delårsrapport 2025-Q3

    Annual reports, prospectus etc.